REG - Adv Medical Solutns. - Director/PDMR and PCA Shareholding

Advanced Medical SolutionsAnnouncement

23/03/2022 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220323:nRSW8057Fa&default-theme=true

RNS Number : 8057F  Advanced Medical Solutions Grp PLC  23 March 2022

     23 March 2022

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that it was
notified on 18 March 2022 that on the same day Chris Meredith, who is a
Director and PDMR, had sold 7,200 Ordinary Shares of 5p held on his behalf and
5,800 Ordinary Shares of 5p held on behalf of Ingrid Meredith, a PCA of Chris
Meredith, both in the name of Platform Securities Nominees Limited
("Nominee"), at a price of 286.5p per Ordinary Share.

 

The Company was also informed that at the same time Individual Savings
Accounts ("ISA's") held in the name of Chris Meredith purchased 7,200 Ordinary
Shares of 5p at a price of 286.7p per Ordinary Share and ISA's held in the
name of Ingrid Meredith purchased 5,800 Ordinary Shares of 5p at a price of
286.7p per Ordinary Share.

 

The number of shares, and the beneficial ownership of the shares, held by
Chris Meredith and Ingrid Meredith remains unchanged.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Director/PDMR
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Sale of 7,200 Ordinary Shares of 5p held in the name of the
     Nominee

     ·        Purchase of 7,200 Ordinary Shares of 5p by an ISA held in the
     name of Chris Meredith
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)                                                 Volume(s)
     Sale of shares from Nominee holding at 286.5p per share  7,200
     Purchase by ISA at 286.7p per share                      7,200

 
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume: 7,200

     Aggregated price: 286.5p
 e)  Date of the transaction: 18/03/2022
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 7,200

Aggregated price: 286.5p

e)

Date of the transaction: 18/03/2022

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Ingrid Meredith
 2.  Reason for the notification
 a)  Position/status: PCA of Chris Meredith
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Sale of 5,800 Ordinary Shares of 5p held in the name of the
     Nominee

     ·        Purchase of 5,800 Ordinary Shares of 5p into ISA's held in
     the name of Ingrid Meredith
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)                                                 Volume(s)
     Sale of shares from Nominee holding at 286.5p per share  5,800
     Purchase by ISA's at 286.7p per share                    5,800

 
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume: 5,800

     Aggregated price: 286.5p
 e)  Date of the transaction: 18/03/2022
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 5,800

Aggregated price: 286.5p

e)

Date of the transaction: 18/03/2022

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

- End -

 

 

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Matthew Cole  AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                           Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made three acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSEVVIVFIF